Sibrotuzumab manufacturers
- Sibrotuzumab
-
- $313.00
-
2026-07-27
- CAS:216669-97-5
- Purity: 95.00%
- Supply Ability: 10g
|
| | Sibrotuzumab Basic information |
| Product Name: | Sibrotuzumab | | Synonyms: | Sibrotuzumab;Research Grade Sibrotuzumab (DHG32201);BIBH 1|||Anti-Human FAP Recombinant Antibody;Sibrotuzumab (anti-FAP) | | CAS: | 216669-97-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Sibrotuzumab Structure]() |
| | Sibrotuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Sibrotuzumab Usage And Synthesis |
| Uses | Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC)[1]. | | References | [1] Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. PMID:12738716
[2] Kobayashi T, et al., Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody. Mol Cancer Ther. 2024 Jul 2;23(7):1031-1042. |
| | Sibrotuzumab Preparation Products And Raw materials |
|